{"id":2011,"date":"2023-09-05T21:09:11","date_gmt":"2023-09-05T18:09:11","guid":{"rendered":"https:\/\/www.vet-ebooks.com\/vetdrugslist\/?p=2011"},"modified":"2023-08-31T21:19:09","modified_gmt":"2023-08-31T18:19:09","slug":"masitinib-mesylate","status":"publish","type":"post","link":"https:\/\/www.vet-ebooks.com\/vetdrugslist\/masitinib-mesylate\/","title":{"rendered":"Masitinib Mesylate"},"content":{"rendered":"

Masitinib Mesylate In Dogs & Cats: Uses, Dosage and Side Effects<\/strong><\/p>\n

$\"Masitinib$ <\/p>\n\n

Overview<\/strong><\/h2>\n
\n
In vitro selective and potent protein tyrosine kinase inhibitor with maximal affinity for mutated forms of the c-KIT tyrosine kinase receptor.<\/li>\n
Inhibitors of tyrosine kinase impede the TK receptor pathways required for cell replication.<\/li>\n<\/ul>\n
Uses of Masitinib mesylate<\/strong><\/h2>\n
\n
Treatment of dogs diagnosed with non-resectable mast cell tumours<\/strong>, specifically those classified as Patnaik grade 2 or 3, and preferably with a confirmed mutation in the c-KIT tyrosine kinase receptor.<\/li>\n
Management of atopic dermatitis<\/strong>, inflammatory bowel disease<\/strong>, osteosarcoma<\/strong>, anal sac adenocarcinoma<\/strong>, and haemangiosarcoma in dogs<\/strong>.<\/li>\n
Previous research has examined the utilisation of masitinib in felines afflicted with injection-site sarcoma<\/strong> and asthma.<\/strong><\/li>\n<\/ul>\n
\n $\"Vet$ <\/a><\/div>\n\n
Dose of Masitinib mesylate in Dogs and Cats<\/strong><\/h2>\n
Dogs:<\/strong><\/p>\n
\n
All uses:<\/span> 11\u201314 mg\/kg p.o. q24h (usually 12.5 mg\/kg p.o. q24h).<\/li>\n<\/ul>\n
Cats:<\/strong><\/p>\n
\n
Limited evidence<\/span>: 50 mg per cat p.o. q24\u201348h has been administered to healthy cats.<\/li>\n<\/ul>\n
\n \n \n